Biotech stocks were among 2017's best performers, until news broke in October that congressional Republicans ditched efforts to repeal and replace Obamacare.
While the rest of the market was still soaring, the Wall Street herd simply turned its attention elsewhere - but that was a big mistake.
Anyone who's very familiar with the bioscience/pharmaceutical sector will tell you investing in experimental drugs can be an object lesson in volatility.
As the drugs progress toward FDA approval or denial, the stock prices of the companies backing them can be in for the same volatile ride.
A stock's surge or decline is often premised on general assumptions about the likelihood of FDA approval.
But within specific bioscience sectors, that likelihood varies... widely.
That's why I wanted to navigate through some types of drugs that generate a lot of enthusiasm but often crash before delivery.
That way you can avoid some of the downside risk of this often lucrative market...
Healthcare spending is expected to soar through 2025 to make up 20% of total GDP.
Meanwhile, the massive baby boomer generation will likely be getting old by that year.
To profit from both trends, you should invest in this biotech stock today...
Finding the best biotech stocks to buy now can be exhausting, especially when investors have to read pages of technical jargon to find out what each company does.
That's why we've made it easy for Money Morning readers.
GW Pharmaceuticals Inc. stock is tanking this morning after releasing its quarterly earnings report and a pipeline update after the closing bell yesterday.
Despite the news, we're still bullish on GWPH.
The two biotech companies we're recommending today are expected to cash in big with medical marijuana.
The stocks of both biotech companies are expected to gain at least 25% in the next 12 months because of their new marijuana-based drugs.
Here's what you need to know to profit from the biotech trend of medical marijuana today...
One of the best biotech stocks this year is positioned to cash in on the convergence of two major trends in the biotech industry.
This convergence could propel the stock to gains of as much as 130% in the next 12 months.
Here's everything you need to know to cash in on these profitable trends...
This month's biotech penny stocks to watch have gained over 35% in the last 30 days alone, with one gaining as much as 133%.
But there is a better biotech stock to buy right now that also allows you to invest in medical marijuana at the same time.
The latest biotech news is showing a revolutionary drug development process that will completely change the way biotech companies develop new drugs.
The technology can also net investors huge gains if they get in before Wall Street figures out how to invest in it.
Here's how you can get in on the ground level of this revolutionary new technology...
Tag Page Excerpt: Novavax stock cratered today despite positive clinical trial data for its RSV F vaccine.
While the data was positive, it did little to assure investors that the vaccine would make it to phase 3 trials and beyond.
Here's what you need to know about NVAX today...
These 3 biotech stocks to watch are all positioned to rise with a common catalyst.
Analysts think this upcoming catalyst could cause one of these biotech stocks to gain nearly 140% in the next 12 months.
Here's what you need to watch with these biotech stocks in 2017...
We've put together a list of our top three best biotech stocks to buy now.
All three of them have a potential catalyst that could spur massive gains in the next year, and one of these biotech stocks could gain over 180% in 12 months.
Our expert has put together a set of biotech-buying guidelines to make finding the best biotech stocks to buy simple and profitable.
Using his guidelines, we've found three biotech stocks about to skyrocket.
One of them on our list could gain as much as 270% in the next 12 months...
Tag Page Excerpt: These cheap biotech stocks to buy could gain as much as 180% in the next 12 months.
Their rapid stock price gains are largely due to the new drugs these companies are releasing.
Our biotech ETF buy has tripled the gains of the Dow since we first recommended it three-and-a-half years ago.
We expect those market-beating gains to continue because of these 4 catalysts.
Not to mention, one of the stocks in the fund is set to gain as much as 178% this year...
